4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase.Hanan, E.J., Baumgardner, M., Bryan, M.C., Chen, Y., Eigenbrot, C., Fan, P., Gu, X.H., La, H., Malek, S., Purkey, H.E., Schaefer, G., Schmidt, S., Sideris, S., Yen, I., Yu, C., Heffron, T.P.
(2016) Bioorg Med Chem Lett 26: 534-539
- PubMed: 26639762
- DOI: https://doi.org/10.1016/j.bmcl.2015.11.078
- Primary Citation of Related Structures:
5EDP, 5EDQ, 5EDR
- PubMed Abstract:
The treatment of epidermal growth factor receptor (EGFR)-driven non-small cell lung cancers with the T790M resistance mutation remains a significant unmet medical need. We report the identification of 4-aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of EGFR, with excellent activity against the T790M resistance double mutants and initial single activating mutants. Using an optimization strategy focused on structure-based design and improving PK properties through metabolite identification, we obtained advanced leads with high oral exposure.
Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, United States.